Abbvie Dividend Stock Analysis: Patents Play

In Moat versus growth investing, companies could be classified into growth categories or moat categories. Investors need to be very careful in this field.
AbbVie will wear a new identity after the Allergan acquisition
source: freepik

The biggest issue is of course the patent of Humira which will expire in 2023. If sales of that antirheumatic drug tumble, dividends will consequently follow and make AbbVie’s status as a dividend darling questionable. Here we try to dig deeper and give a detailed perspective about what really happens through our AbbVie dividend stock analysis.

Continue reading “Abbvie Dividend Stock Analysis: Patents Play”